Vascular Diseases
Also known as: Vein, Venous, Infarction, Stroke, Hyperplasia
Methodology & AI Transparency ⓘ
Vascular Diseases Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are vascular diseases? Your vascular system is your body's network of blood vessels.
- 2 Real-world patient consensus: Synonyms for Vascular Diseases (I73.9): Vein, Venous, Infarction (Blood Pressure).
- 3 Typical cash cost range: Primary evaluation for Vascular Diseases incorporates renal-electrolyte panels [Vascular Diseases I73.9] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Vascular Diseases: maintaining Home Seated Blood in Vascular Diseases (I73.9: Pressure) within < 120/75 mmHg (I73.9).
Ask our AI Specialists anything about Vascular Diseases
What Is Vascular Diseases?
What are vascular diseases? Your vascular system is your body's network of blood vessels. It includes your: Arteries, which carry oxygen-rich blood from your heart to your tissues and organs Veins, which carry the blood and waste products back to your heart Capillaries, which are tiny blood vessels that connect your small arteries to your small veins. The walls of the capillaries are thin and leaky, to allow for an exchange of materials between your tissues and blood. Vascular diseases are conditions which affect your vascular system. They are common and can be serious.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Vascular Diseases (code I73.9) is venous valve incompetence [Vascular Diseases I73.9], Cross-referenced with NIH MeSH (Vascular Diseases), which High Blood Pressure & Vascular Health clinicians address while surveilling Home Seated Blood in Vascular Diseases (I73.9: Pressure) (< 120/75 mmHg (I73.9)).
Common Symptoms & Clinical Signs
- • Arteries, which carry oxygen-rich blood from your heart to your tissues and organs
- • Veins, which carry the blood and waste products back to your heart
- • Presentation of Vascular Diseases (I73.9): calf cramping or in Vascular Diseases (I73.9: claudication triggered by)
- • Secondary Vascular Diseases clinical sign: localized extremity swelling, in Vascular Diseases (I73.9: warmth, or venous)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vascular Diseases Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I73.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Home Seated Blood in Vascular Diseases (I73.9: Pressure) | < 120/75 mmHg (I73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Vascular Diseases I73.9] | 1.00 – 1.30 (I73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Vascular Diseases (I73.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I73.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vascular Diseases
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nufymco (Ranibizumab-Leyk) Nufymco • RxCUI RXN-B707102172 | Vascular Endothelial Growth Factor Inhibitor | 82% | $0.5600 | $ 48.82 /mo |
| Jobevne (Bevacizumab-Nwgd) Jobevne • RxCUI 2712055 | Vascular Endothelial Growth Factor Inhibitor | 94% | $1.0200 | $ 81.94 /mo |
| Ranibizumab Lucentis, Susvimo • RxCUI 1864423 | Vascular Endothelial Growth Factor Inhibitor | 75% | $0.6200 | $ 33.61 /mo |
| Bevacizumab-Vikg Lytenava • RxCUI RXN-82491025-2275 | Vascular Endothelial Growth Factor Inhibitor | 85% | $2.9000 | $ 125.95 /mo |
| Aflibercept Eylea, Enzeevu • RxCUI 1232154 | Vascular Endothelial Growth Factor Inhibitor | 91% | $3.5400 | $ 151.87 /mo |
| Zaltrap (Ziv-Aflibercept) Zaltrap • RxCUI 1723189 | Vascular Endothelial Growth Factor Inhibitor | 80% | $2.4000 | $ 181.30 /mo |
| Bevacizumab-Bvzr Zirabev • RxCUI RXN-00690342-2280 | Vascular Endothelial Growth Factor Inhibitor | 83% | $1.4200 | $ 66.01 /mo |
| Yesafili (Aflibercept-Jbvf) Yesafili • RxCUI RXN-B83257035 | Vascular Endothelial Growth Factor Inhibitor | 94% | $2.7600 | $ 207.22 /mo |
| Ranibizumab-Leyk Nufymco • RxCUI RXN-707102172-2427 | Vascular Endothelial Growth Factor Inhibitor | 91% | $3.2700 | $ 140.94 /mo |
| Pavblu (Aflibercept-Ayyh) Pavblu • RxCUI 2696260 | Vascular Endothelial Growth Factor Inhibitor | 77% | $0.3500 | $ 33.70 /mo |
| Lytenava (Bevacizumab-Vikg) Lytenava • RxCUI RXN-B82491025 | Vascular Endothelial Growth Factor Inhibitor | 87% | $0.6900 | $ 58.18 /mo |
| Susvimo (Ranibizumab) Susvimo • RxCUI RXN-B50242078 | Vascular Endothelial Growth Factor Inhibitor | 91% | $0.6300 | $ 53.86 /mo |
| Ramucirumab Cyramza • RxCUI RXN-00027678-2828 | Vascular Endothelial Growth Factor Receptor 2 Antagonist | 80% | $2.1200 | $ 94.36 /mo |
| Cyramza (Ramucirumab) Cyramza • RxCUI RXN-B00027678 | Vascular Endothelial Growth Factor Receptor 2 Antagonist | 86% | $3.1800 | $ 237.46 /mo |
| Faricimab Vabysmo • RxCUI 2591588 | FDA Prescription Therapeutic Agent | 92% | $1.5200 | $ 70.06 /mo |
| Ahzantive (Aflibercept-Mrbb) Ahzantive • RxCUI RXN-B850062908 | Vascular Endothelial Growth Factor Inhibitor | 87% | $1.9000 | $ 145.30 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vascular Diseases)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
Vascular Diseases Patient Community & “People Like Me” Threads
Filter Vascular Diseases community threads and patient logs by age, biological sex, dosage, and treatment duration.